"Development of the proteasome inhibitor Velcade™ (bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

Research output: Contribution to journalArticle

15 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)328-329
Number of pages2
JournalCancer Investigation
Volume22
Issue number2
StatePublished - 2004

Fingerprint

Interinstitutional Relations
Boronic Acids
Pyrazines
Federal Government
Proteasome Inhibitors
Drug Design
Drug Industry
Protease Inhibitors
Biomedical Research
Clinical Trials
Neoplasms
Bortezomib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{f7e9ffded3744ccfa91557f523ccd004,
title = "{"}Development of the proteasome inhibitor Velcade™ (bortezomib){"} by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.",
author = "Bold, {Richard J}",
year = "2004",
language = "English (US)",
volume = "22",
pages = "328--329",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - "Development of the proteasome inhibitor Velcade™ (bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

AU - Bold, Richard J

PY - 2004

Y1 - 2004

UR - http://www.scopus.com/inward/record.url?scp=2642586572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642586572&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 328

EP - 329

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -